Delineating the Effects of Tumor Therapies on Prostate Cancer Using Small Animal Imaging Technologies
Abstract
This final report presents the data generated under the grant awarded to Jason S. Lewis, PhD (W81XWH-04-1-0906). This proposal was aimed at delineating the relationship between androgen ablation and hypoxia as well as monitoring changes in blood flow, metabolism, oxygenation, vascular permeability and cellular proliferation in animal models of prostate cancer using small animal PET. In this final report we detail the advances made in relation to the original Statement of Work. During this funding period we have shown that, (1) it is not possible to delineate changes in prostate tumor glucose utilization with 2-[18F]Fluoro-2-deoxyglucose (FDG) and microPET following androgen ablation treatment; (2) it is not possible to monitor alterations in cellular proliferation with 18F-3 -deoxy-3 -fluorothymidine (18F-FLT) and microPET following treatment; (3) 64Cu-ATSM uptake is affected by the presence of fatty acid synthase (FAS) and, therefore, may not be suitable for the imaging of hypoxia in prostate tumors as the redox balance is changed, and (4) that 1-11C-acetate is a marker for FAS. This work has led to the presentation of six abstracts at international meetings and two peer-reviewed manuscripts. These findings are promising as they suggest a possible biomarker for more effective treatments in prostate cancer patients, and possibly others, since FAS expression has shown links to poor prognosis in other cancers as well. Moreover, since FAS inhibitors are being developed as anti-tumor agents, this technology also provides a unique opportunity to monitor the effectiveness and the validation of new FAS inhibitors for translation into a clinical setting.
Document Details
- Document Type
- Technical Report
- Publication Date
- Nov 01, 2007
- Accession Number
- ADA476780
Entities
People
- Jason S. Lewis
Organizations
- University of Missouri